statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 208,200...

Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Up 113.1% in March

Appendix: Comparison of PsiGAD Treatments to Existing Registered Treatments for Anxiety

 Figure: meta-analysis(1) of psychotropic medications for GAD, as measured by the HAM-A; the best...

Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology...

Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Is Incannex Healthcare (NASDAQ:IXHL) In A Good Position To Invest In Growth?

Highlights: Clarion's Head of Psychiatry, Professor Suresh Sundram, has been approved by the TGA to prescribe MDMA for Post-traumatic Stress Disorder and psilocybin for Treatment-resistant...

Clarion Clinics Open for Psychedelic-Assisted Treatments

MELBOURNE, Australia and NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), ('Incannex' or the 'Company'), a pharmaceutical company developing novel medicinal...

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Highlights: 72 patients treated at purpose-built facilities within Monash University, Melbourne, Australia.Topline results from the trial anticipated within current Q1 2024.FDA IND application is...

Incannex Completes Dosing and Therapy in Phase 2  PsiGAD  Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences

MELBOURNE, AustraliaandNEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), ('Incannex' or the 'Company'), a pharmaceutical company developing unique...

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Incannex Healthcare, Inc. is a clinical stage pharmaceutical development company, which engages in the research and development associated with medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It operates through the following segments: Psychedelic Products, Cannabinoid Products, and Corporate. The Psychedelic Products segment is involved in the use of psychedelic medicine and therapies for the treatment of mental health disorders. The Cannabinoid Products segment focuses on the use of medicinal cannabinoid products. The Corporate segment includes management of the organization, capital management, and management of resources. The company was founded on April 27, 2001 and is headquartered in New York, NY.

Volume	3,855.00
52-Wk High	$12.68
52-Wk Low	$1.96

IXHL Incannex Healthcare Limited - ADR

About

Feed

News

Fundamentals